Find where to buy products from UK suppliers, including: distributors, industrial manufacturers, wholesalers, raw ingredients, bulk supplies and finished goods for sale.
Search for products or services, then visit the suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the USA.
| Product | Description | |
|---|---|---|
| Betaxolol Impurities | Betaxolol Impurities encompass a range of chemical variants linked to the beta-adrenergic blocker Betaxolol. These impurities are crucial in the biomedical industry for assessing the purity and safety of Betaxolol formulations, which are primarily used in treating hypertension and glaucoma, ensuring drug efficacy and regulatory compliance. Group: Pharmaceutical. Pack Sizes: 1mg; 1g; 10g. Molecular formula: Custom synthesis is available. Send your inquiries for more information. |  London |
| Levobetaxolol HCl | Levobetaxolol exhibits a higher affinity at cloned human β1 and β2 receptors with Ki value of 0.76 nM and 32.6 nM, respectively. Group: Pharmaceutical. CAS No. 116209-55-3. Pack Sizes: 1 g. Product ID: B2693-161367. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| (R)-O-Demethylmetoprolol | (R)-O-Demethylmetoprolol is an impurity of Betaxolol, which is a selective beta1 adrenergic receptor blocker for the treatment of hypertension and glaucoma. Group: Pharmaceutical. CAS No. 131564-70-0. Pack Sizes: 100 mg. Product ID: B0436-284904. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| (S)-O-Demethylmetoprolol | (S)-O-Demethylmetoprolol is an impurity of Betaxolol, which is a selective beta1 adrenergic receptor blocker for the treatment of hypertension and glaucoma. Group: Pharmaceutical. CAS No. 131564-69-7. Pack Sizes: 100 mg. Product ID: B0436-284903. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
Our database is helping our users find suppliers everyday.
